Concomitant cardiac amyloidosis did not significantly affect 1-year all-cause mortality in severe aortic stenosis patients undergoing TAVI (OR 0.94, 95% CI 0.56-1.58).
Does concomitant cardiac amyloidosis impact 1-year all-cause mortality in patients with severe aortic stenosis?
The presence of concomitant cardiac amyloidosis does not significantly worsen 1-year all-cause mortality in patients with severe aortic stenosis, including those undergoing TAVI.
Absolute Event Rate: 0% vs 0%
Abstract Background Severe aortic stenosis (AS) and cardiac amyloidosis (CA) frequently coexist in elderly populations. The prognostic significance of dual pathology CA-AS in the context of transcatheter aortic valve implantation (TAVI) is not widely established. We performed a systematic review and meta-analysis to compare 1-year mortality of patients with concomitant CA-AS to those with isolated AS. Background PubMed, EMBASE, Web of Science and Cochrane databases were searched until February 16th 2025 for all multivariable-adjusted or propensity-matched observational studies evaluating clinical outcomes in CA-AS patients. Summary odds ratios with 95% confidence intervals (CI) were calculated using random-effects model, with pre-specified subgroup analyses for patients undergoing TAVI. Results Fifteen observational studies (775319 severe AS patients) met inclusion criteria. The mean follow-up duration was 22.4 months, mean age was 81.5 years and 56.3% were men. The pooled odds ratio for all-cause mortality in CA-AS patients was 1.21 (95% CI 0.81-1.80). There was no statistically significant difference in 1-year all-cause mortality between CA-AS and isolated AS (OR 1.38, 95% CI 0.80-2.37) or between CA-AS patients undergoing TAVI compared to medical management (OR 0.94, 95% CI 0.56-1.58). Conclusion The presence of concomitant CA does not significantly impact the 1-year all-cause mortality of patients with severe AS undergoing TAVI.Figure 1:Pooled OR (95% CI) CA-AS Figure 2:TAVI vs Medical (CA-AS)
Zaka et al. (Sat,) reported a other. Concomitant cardiac amyloidosis did not significantly affect 1-year all-cause mortality in severe aortic stenosis patients undergoing TAVI (OR 0.94, 95% CI 0.56-1.58).